

From: [Hasford, Justin](#)
To: [Trials](#)
Cc: [Diner, Bryan](#); [Goldberg, Joshua](#); [Officer, Kassandra](#); [\(Dowty\) Robinson, Lauren](#); [Kim, Kyu Yun](#); [Torczon, Richard \(External\)](#); [Mills, Jad](#); [Thomas, Tasha](#); [Berman, Richard](#); [Frese, Bradford C.](#); [Christopher J. Sorenson](#); [Andrew O. Larsen](#); [Melissa M. Hayworth](#)
Subject: Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd., IPR2022-00722
Date: Wednesday, August 9, 2023 6:16:32 PM
Attachments: [image001.png](#)

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Board:

Pursuant to 37 C.F.R. 42.123, Patent Owner respectfully requests a conference call to seek authorization to submit supplemental information to the Board in IPR2022-00722, in particular the expert report of Dr. Zhou that Mylan recently served in Case No. 22-cv-20 (N.D. W.Va.). Counsel for Petitioner and Patent Owner met and conferred on August 7, 2023, and Petitioner opposes such authorization.

Petitioner's position is that Patent Owner has not satisfied the standard for the relief requested, and that the Zhou report should not be admitted without affording Petitioner an opportunity to provide the Board with briefing about its contents and to submit materials relied upon by Dr. Zhou.

Counsel for the parties are available after 9 am Pacific on Friday, August 11 and on Thursday, August 17.

Respectfully submitted,

Justin Hasford

Justin J. Hasford | [Bio](#)
Partner

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
901 New York Avenue, NW, Washington, DC 20001-4413
+1 202 408 4000 | fax +1 202 408 4400 | justin.hasford@finnegan.com
www.finnegan.com | [LinkedIn Profile](#) | [Finnegan AIA Blog](#)

FINNEGAN

This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have received this message in error, please advise the sender by return e-mail and delete it from your mailbox. Thank you.

This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have received this message in error, please

advise the sender by return e-mail and delete it from your mailbox. Thank you.